Carles Vilariño-Güell started his career with a biology degree from the University of Barcelona, Spain and a Ph.D. degree in molecular genetics from the University of Leicester, England, UK. He held two postdoctoral positions, first at the University of Oxford, England, UK, and then at the Institute of Neurology, University College London, UK, where he started his career studying the molecular bases of neurodegeneration. In 2007, he moved to the Division of Neurogenetics within the Department of Neuroscience at Mayo Clinic, Rochester, Minn, USA. Vilariño-Güell became an Assistant Professor of molecular neuroscience in 2009, initiating new research programs in the molecular genetics of restless legs syndrome and essential tremor. In 2010, he relocated to The University of British Columbia, Vancouver, Canada, for an opportunity to expand his research effort in neurologic and neurodegenerative disease with primary focus on multiple sclerosis. Vilariño-Güell is an Expert Molecular Geneticist. He has dedicated his career to the identification and understanding of genetic mutations leading to familial forms of neurological disease, and the analysis of complex epidemiological data in ethnically distinct populations, to identify susceptibility variants acting as early precursors of disease development. To date, Vilariño-Güell has published over 50 articles in many prestigious journals including New England Journal of Medicine and Nature Genetics. His research interests include the identification of LINGO1 as the first genetic risk factor common to Parkinson disease and essential tremor, pathogenic MEIS1 mutations for restless legs syndrome, DCTN1 mutations in Perry syndrome, classical linkage analysis for the identification of eIF4G1 mutations in Parkinson disease patients, and more recently, the implementation of next-generation sequencing technologies for the identification of VPS35 and DNAJC13 mutations leading to Parkinson disease.
Biography Updated on 12 September 2012